Results 201 to 210 of about 361,742 (335)

The cervico‐vaginal DNA methylation WID‐qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The DNA methylation‐based WID‐qEC test has been validated for the accurate detection of endometrial and cervical cancers using cervico‐vaginal samples. However, a small proportion of women test positive despite the absence of these cancers. This study explored the associated biological and clinical characteristics to inform potential follow‐
Elisa Redl   +18 more
wiley   +1 more source

Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission. [PDF]

open access: yesFront Oncol
De Tommasi O   +9 more
europepmc   +1 more source

Combination of transvaginal ultrasound with cervical cancer screening contributes to early detection of ovarian cancer: Clinical trial

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective Early detection of ovarian cancer at stage I is important to improve patients‘ prognosis. The goal of this study was to examine if transvaginal ultrasound (TVU) performed at the same time as cervical cancer screening can facilitate early detection of ovarian cancer.
Hiromasa Fujita   +5 more
wiley   +1 more source

Glycation Product Synthesized in Anhydrous Conditions Mimics an Epitope in Epithelial and Mesenchymal Tissues. [PDF]

open access: yesBiomedicines
Czech M   +6 more
europepmc   +1 more source

NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones.

open access: yesOncology Report, 2012
H. Liao   +6 more
semanticscholar   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori   +11 more
wiley   +1 more source

Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

open access: yesInterdisciplinary Medicine, EarlyView.
We assembled National Cancer Center–Clinical Diagnostics Knowledgebase, a clinical genomic knowledgebase of 6935 tumors with matched normal samples, revealing key somatic alterations and actionable variants (70.2% of the cohort). Enrichment of certain different gene mutations was observed between Chinese and American populations, along with a strong ...
Hongrui Li   +10 more
wiley   +1 more source

Secondary <i>POLE</i> Mutation Drives Metastasis in Hereditary Breast and Ovarian Cancer: Revealing Fallopian Tube Ultramutation. [PDF]

open access: yesJCO Precis Oncol
Jisaka M   +9 more
europepmc   +1 more source

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

open access: yesCancer Discovery, 2017
O. Kondrashova   +34 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy